| 

Strategy

"What we develop we can also produce"

We concentrate on those segments of the value-added chain where our past success have enabled us to accumulate expertise and experience. These include the synthesis of active pharmaceutical ingredients (APIs), pre-clinical and clinical development and regulatory procedures. This strategy also encompasses being able to produce everything we develop - a key to retaining substance-specific knowledge in-house and achieving long-term competitive advantages. Short development times, rapid marketing authorisations and early product launches are other central aspects of our strategy.

 

Our clearly-definded strategy as a Specialty Pharmaceuticals Company, the selection of high-potential therapeutic areas and the on-going internationalisation of our operations have placed us in a strong position from which to exploit the opportunities for growth generated by our operational divisions.

 

Go to top
Print